Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25, Briefing.com reports. Supernus Pharmaceuticals had a return on equity of 7.94% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. The company’s revenue was up 14.2% compared to the same quarter last year. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN traded up $2.43 during trading on Wednesday, reaching $37.17. The stock had a trading volume of 106,420 shares, compared to its average volume of 447,691. The stock has a market cap of $2.05 billion, a PE ratio of 32.47 and a beta of 0.86. Supernus Pharmaceuticals has a one year low of $23.05 and a one year high of $39.37. The firm’s 50 day moving average price is $33.02 and its two-hundred day moving average price is $30.54.

Analysts Set New Price Targets

SUPN has been the subject of a number of recent analyst reports. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.